Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using beta-funaltrexamine

JU Adams, CA Paronis and SG Holtzman

Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia.

Morphine is the prototypic mu-opioid analgesic; however, in certain situations in vitro, morphine behaves as a partial agonist. To assess the relative intrinsic activity of morphine and three other mu-opioid analgesics in vivo, beta-funaltrexamine (beta-FNA), an irreversible antagonist selective for the mu receptor, was used to reduce the effective receptor reserve. By using a stereotaxic device, 1.25 to 20 micrograms of beta-FNA was infused into the lateral ventricle of rats. Twenty-four hours later, animals were tested in the tail-flick assay with cumulative doses of morphine, levorphanol, methadone or fentanyl. Pretreatment with 2.5 micrograms of beta-FNA induced parallel rightward shifts of both the morphine and levorphanol dose-effect curves and 5.0 micrograms of beta-FNA reduced the maximum analgesic effect of these agonists. Methadone surmounted the antagonism of 5.0 micrograms of beta- FNA; 10 micrograms was required to reduce the maximum analgesic effect of methadone. Fentanyl overcame the blockade induced by both 5.0 and 10 micrograms of beta-FNA. Only with a pretreatment dose of 20 micrograms of beta-FNA was the maximum analgesic effect of fentanyl reduced. Thus, when a certain proportion of mu receptors is inactivated, i.e., with 5.0 micrograms of beta-FNA, fentanyl and methadone have the capacity to surmount the blockade, whereas morphine and levorphanol do not. This suggests that fentanyl and methadone have higher intrinsic efficacies than do morphine and levorphanol. Thus, a strategy used widely in vitro was applied successfully in vivo to assess relative intrinsic activities of a series of mu-opioid agonists.

Volume 255, Issue 3, pp. 1027-1032, 12/01/1990
Copyright © 1990 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				S. P. Hume, A. R. Lingford-Hughes, V. Nataf, E. Hirani, R. Ahmad, A. N. Davies, and D. J. Nutt Low Sensitivity of the Positron Emission Tomography Ligand [11C]Diprenorphine to Agonist Opiates J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 661 - 667. [Abstract] [Full Text] [PDF]

				B. D. Fischer and L. A. Dykstra Interactions between an N-Methyl-D-aspartate Antagonist and Low-Efficacy Opioid Receptor Agonists in Assays of Schedule-Controlled Responding and Thermal Nociception J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1300 - 1306. [Abstract] [Full Text] [PDF]

				J. Celver, M. Xu, W. Jin, J. Lowe, and C. Chavkin Distinct Domains of the {micro}-Opioid Receptor Control Uncoupling and Internalization Mol. Pharmacol., March 1, 2004; 65(3): 528 - 537. [Abstract] [Full Text] [PDF]

				R. M. Allen, A. L. Granger, and L. A. Dykstra The Competitive N-Methyl-D-aspartate Receptor Antagonist (-)-6-Phosphonomethyl-deca-hydroisoquinoline-3-carboxylic Acid (LY235959) Potentiates the Antinociceptive Effects of Opioids That Vary in Efficacy at the {micro}-Opioid Receptor J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 785 - 792. [Abstract] [Full Text] [PDF]

				A. C. Barrett, E. S. Smith, and M. J. Picker Use of Irreversible Antagonists to Determine the Relative Efficacy of {micro}-Opioids in a Pigeon Drug Discrimination Procedure: Comparison of {beta}-Funaltrexamine and Clocinnamox J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 1061 - 1070. [Abstract] [Full Text] [PDF]

				A. Duttaroy, J. Gomeza, J.-W. Gan, N. Siddiqui, A. S. Basile, W. D. Harman, P. L. Smith, C. C. Felder, A. I. Levey, and J. Wess Evaluation of Muscarinic Agonist-Induced Analgesia in Muscarinic Acetylcholine Receptor Knockout Mice Mol. Pharmacol., November 1, 2002; 62(5): 1084 - 1093. [Abstract] [Full Text] [PDF]

				E. A. Walker and A. M. Young Clocinnamox Distinguishes Opioid Agonists According to Relative Efficacy in Normal and Morphine-Treated Rats Trained to Discriminate Morphine J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 101 - 110. [Abstract] [Full Text] [PDF]

				S. E. Robinson and M. J. Wallace Effect of Perinatal Buprenorphine Exposure on Development in the Rat J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 797 - 804. [Abstract] [Full Text] [PDF]

				J. H. Broadbear, T. L. Sumpter, T. F. Burke, S. M Husbands, J. W. Lewis, J. H. Woods, and J. R. Traynor Methocinnamox Is a Potent, Long-Lasting, and Selective Antagonist of Morphine-Mediated Antinociception in the Mouse: Comparison with Clocinnamox, beta -Funaltrexamine, and beta -Chlornaltrexamine J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 933 - 940. [Abstract] [Full Text]

				M. Valle, M. J. Garrido, J. M. Pavón, R. Calvo, and I. F. Trocóniz Pharmacokinetic-Pharmacodynamic Modeling of the Antinociceptive Effects of Main Active Metabolites of Tramadol, (+)-O-Desmethyltramadol and (-)-O-Desmethyltramadol, in Rats J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 646 - 653. [Abstract] [Full Text]

				P. A. Zaki, D. E. Keith Jr., G. A. Brine, F. I. Carroll, and C. J. Evans Ligand-Induced Changes in Surface {micro}-Opioid Receptor Number: Relationship to G Protein Activation? J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 1127 - 1134. [Abstract] [Full Text]

				D. Morgan, C. D. Cook, and M. J. Picker Sensitivity to the Discriminative Stimulus and Antinociceptive Effects of µ Opioids: Role of Strain of Rat, Stimulus Intensity, and Intrinsic Efficacy at the µ Opioid Receptor J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 965 - 975. [Abstract] [Full Text]

				D. Morgan, C. D. Cook, M. A. Smith, and M. J. Picker An Examination of the Interactions Between the Antinociceptive Effects of Morphine and Various {micro}-Opioids: The Role of Intrinsic Efficacy and Stimulus Intensity Anesth. Analg., February 1, 1999; 88(2): 407 - 407. [Abstract] [Full Text] [PDF]

				A. Alt, A. Mansour, H. Akil, F. Medzihradsky, J. R. Traynor, and J. H. Woods Stimulation of Guanosine-5'-O-(3-[35S]Thio)Triphosphate Binding by Endogenous Opioids Acting at a Cloned Mu Receptor J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 282 - 288. [Abstract] [Full Text]

				R. C. Pitts, R. M. Allen, E. A. Walker, and L. A. Dykstra Clocinnamox Antagonism of the Antinociceptive Effects of Mu Opioids in Squirrel Monkeys J. Pharmacol. Exp. Ther., June 1, 1998; 285(3): 1197 - 1206. [Abstract] [Full Text]

				M. A. Whittington, R. D. Traub, H. J. Faulkner, J. G. R. Jefferys, and K. Chettiar Morphine disrupts long-range synchrony of gamma oscillations in hippocampal slices PNAS, May 12, 1998; 95(10): 5807 - 5811. [Abstract] [Full Text] [PDF]

				D. E. Selley, Q. Liu, and S. R. Childers Signal Transduction Correlates of Mu Opioid Agonist Intrinsic Efficacy: Receptor-Stimulated [35S]GTPgamma S Binding in mMOR-CHO Cells and Rat Thalamus J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 496 - 505. [Abstract] [Full Text]

				M. J. Picker Discriminative Stimulus Effects of the Mixed-Opioid Agonist/Antagonist Dezocine: Cross-Substitution by Mu and Delta Opioid Agonists J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1009 - 1017. [Abstract] [Full Text]